Clostridium difficile is a causative agent for various gut disorders with symptoms such as diarrhea, nausea, colon inflammation, and others. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of C. difficile bacteria. Common symptoms of clostridium difficile infection include watery diarrhea, dehydration, fever, nausea, loss of appetite, and weight loss. Life threatening symptoms of the disease includes abdominal distension, severe abdominal pain, and profuse diarrhea. Clostridium difficile infection management includes diagnosis of the infection using various tests and medication therapies using antibiotics such as Vancomycin and Fidaxomicin.
Global clostridium difficile diagnostics market is estimated to be valued at US$ 838.05 million in 2022 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2022-2030).
Figure 1.Global Clostridium Difficile Diagnostics Market Share (%), by Diagnostic Test, 2022
Global Clostridium Difficile Diagnostics Market- Drivers
The increasing prevalence of clostridium difficile infection (CDI) is anticipated to boost the demand for its diagnosis, which is expected to drive the global clostridium difficile diagnostics market growth. For instance, according to the data published by Cureus, an open access medical journal, in December 2021, C. difficile infection (CDI) impacts 13 in every 1,000 patients globally and about 75% of cases are considered hospital-acquired. Higher rates of hospital admissions and antibiotic use have been linked with increased rates of healthcare-associated CDI (HA-CDI). Nosocomial CDI is linked to increased morbidity and mortality.
Moreover, increasing approval of diagnostics tests/assays by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in November 2018, Singulex, Inc., an immunodiagnostics company, announced the commercial introduction of its Clarity C. difftoxin A/B assay, a rapid, high-sensitivity, high-precision, for C. difficile toxin testing. The assay matches the sensitivity and specificity of cell cytotoxicity neutralization assays, giving it the potential to reduce the false positives of polymerase chain reaction-based tests and the false negatives of current, less-sensitive toxin immunoassays.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 838.05 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 7.1% | 2030 Value Projection: | US$ 1,450.29 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Clostridium Difficile Diagnostics Market Share (%), by Region, 2022
Global Clostridium Difficile Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. COVID-19 had limited impact on the global clostridium difficile diagnostics market. For instance, according to an article published by Elsevier Inc., in August 2022, during the COVID-19 pandemic, several factors, such as improved hand hygiene, social distancing, and restricted hospital referral, may have had an influence on the epidemiology of Clostridioides difficile infections (CDI).
Global Clostridium Difficile Diagnostics Market: Key Developments
In 2021, the two German companies, Novatec Immundiagnostica GmbH and Virotech Diagnostics GmbH, collaborated to form Gold Standard Diagnostics Europe. The newly formed company is focusing on both human and veterinary markets, as it is manufacturing diagnostic kits for infectious diseases (bacterial, viral, and parasitic diseases), hormones, and autoimmunity.
Global Clostridium Difficile Diagnostics Market: Restraint
Low awareness about clostridium difficile infection symptoms and associated effects is expected to restrain the growth of the clostridium difficile diagnostics market over the forecast period.
For instance, according to an article published by Cambridge University, in 2017, titled ‘Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia’, an awareness survey population was conducted amongst University hospital staff (i.e. doctors, non-clinical medical professionals, and paramedics) and students (i.e. undergraduates and postgraduates) who were involved with in-hospital patient care, which comprised of five multiple-choice questions.
Global Clostridium Difficile Diagnostics Market- Key Players
Major players operating in the global clostridium difficile diagnostics market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc
Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Clostridium difficile is a disease caused by bacteria. The illness manifests as a variety of symptoms, such as diarrhea, nausea, and colon inflammation. Furthermore, since antibiotics kill healthy bacteria in the body and promote the growth of C. difficile bacteria, they are also responsible for clostridium difficile infection when taken frequently. Watery diarrhoea, dehydration, fever, nausea, loss of appetite, and weight loss are typical signs of clostridium difficile infection. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.
Market Dynamics
Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients